Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Corey

Showing results (1-10 of 418) with videos related to

Pageof 42
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugatesDavid R Corey
The Journal of Clinical Investigation|December 7, 2007
Chemical modification: the key to clinical application of RNA interference?David R Corey
JAMA Neurology|November 2, 2016
Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-ReplyDavid R Corey
Nucleic Acid Therapeutics|November 21, 2024
It is Time to Revisit miRNA TherapeuticsDavid R Corey
JAMA Neurology|August 2, 2016
Synthetic Nucleic Acids and Treatment of Neurological DiseasesDavid R Corey
Methods (San Diego, Calif.)|February 22, 2001
EditorialD R Corey
Chemical Research in Toxicology|November 18, 2000
Telomerase: an unusual target for cytotoxic agentsD R Corey
Oncogene|February 19, 2002
Telomerase inhibition, oligonucleotides, and clinical trialsDavid R Corey
Nature Neuroscience|February 14, 2017
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyDavid R Corey
Idrugs : the Investigational Drugs Journal|March 9, 2006
EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industryDavid R Corey
Pageof 42

Showing results (1-10 of 418) with videos related to

Sort By:
Pageof 42
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugatesDavid R Corey
The Journal of Clinical Investigation|December 7, 2007
Chemical modification: the key to clinical application of RNA interference?David R Corey
JAMA Neurology|November 2, 2016
Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-ReplyDavid R Corey
Nucleic Acid Therapeutics|November 21, 2024
It is Time to Revisit miRNA TherapeuticsDavid R Corey
JAMA Neurology|August 2, 2016
Synthetic Nucleic Acids and Treatment of Neurological DiseasesDavid R Corey
Methods (San Diego, Calif.)|February 22, 2001
EditorialD R Corey
Chemical Research in Toxicology|November 18, 2000
Telomerase: an unusual target for cytotoxic agentsD R Corey
Oncogene|February 19, 2002
Telomerase inhibition, oligonucleotides, and clinical trialsDavid R Corey
Nature Neuroscience|February 14, 2017
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyDavid R Corey
Idrugs : the Investigational Drugs Journal|March 9, 2006
EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industryDavid R Corey
Pageof 42